 Clinical Study
May 23, 2024
CSIMarket.com - May 23, 2024HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a biopharmaceutical company focused on developing immunotherapeutics based on its innovative arenavirus platform, recently released updated positive results from its Phase 1/2 clinical trial of HB-200. The trial investigated the potential of ...
|
Announcement
May 23, 2024
Breakthrough Results for EVX-01: Promising New Data from Phase 2 Study to be Presented at ASCO 2024 COPENHAGEN, Denmark, May 23, 2024 Evaxion Biotech A/S (NASDAQ: EVAX), a pioneering company in the development of AI-Immunology powered vaccines, is set to present promising new data from its ongoing Phase 2 study ...
|
Clinical Study
May 23, 2024
In recent years, the field of immuno-oncology has witnessed groundbreaking advancements that offer new hope for cancer patients. Mural Oncology, a leading clinical-stage immuno-oncology company, has been at the forefront of this innovation. Two significant developments came to light recently: the presentation of cli...
|
|
 Clinical Study
May 23, 2024
The pharmaceutical industry is abuzz with the exciting news of Corbus Pharmaceuticals Holdings, Inc. releasing updated Phase 1 clinical data for their revolutionary drug, SYS-6002 (CRB-701). This groundbreaking advance in cancer treatment is set to be presented at the prestigious 2024 American Society of Clinical On...
 Clinical Study
May 23, 2024
Innovative Therapeutic Approaches Show Promising Results in Oncology, Genetic Deafness, and Retinal Diseases The landscape of therapeutic interventions is witnessing groundbreaking advancements in the treatment of challenging diseases. Recent presentations at prominent medical conferences have highlighted important...
|
|
Our most Popular Articles
|
Announcement
May 7, 2024
In a recent development, Varonis Systems Inc, a leading data security firm, has announced the integration of prompt monitoring within its highly regarded Microsoft 365 Copilot security offering. This advanced AI-driven monitoring solution is set to reinforce protection against malicious copilot activity, ensuring en...
|
Business Update
August 1, 2024
Elastic (NYSE: ESTC), the leading Search AI company based in San Francisco, has made significant strides in enhancing its Elasticsearch platform s capabilities with new updates and recognitions. The latest announcements solidify Elastic s commitment to creating cutting-edge solutions for AI-driven search application...
|
Management Changes
January 13, 2024
DALLAS, Jan. 12, 2024 - Dorchester Minerals, L.P. (NASDAQ-DMLP), a prominent player in the Energy sector, has announced the appointment of Ms. Lesley Carver as the newly appointed manager of the board of managers of Dorchester Minerals Management GP LLC, effective January 10, 2024. The notification was rec...
|
|
|
Company News
|
Announcement
May 23, 2024
Breakthrough Results for EVX-01: Promising New Data from Phase 2 Study to be Presented at ASCO 2024 COPENHAGEN, Denmark, May 23, 2024 Evaxion Biotech A/S (NASDAQ: EVAX), a pioneering company in the development of AI-Immunology powered vaccines, is set to present promising new data from its ongoing Phase 2 study ...
|
Clinical Study
May 23, 2024
In recent years, the field of immuno-oncology has witnessed groundbreaking advancements that offer new hope for cancer patients. Mural Oncology, a leading clinical-stage immuno-oncology company, has been at the forefront of this innovation. Two significant developments came to light recently: the presentation of cli...
|
Clinical Study
May 23, 2024
Kymera Therapeutics, a leading biotechnology company, is set to make significant scientific contributions at various upcoming medical conferences, presenting new clinical data from their ongoing Phase 1 trials of MDM2 Degrader KT-253 and STAT3 Degrader KT-333. The company s recent announcement regarding scientific p...
|
|
|
Company News
 Clinical Study
May 23, 2024
|
Company News
 Clinical Study
May 23, 2024
|
Company News
 Clinical Study
May 23, 2024
|
More Company News
|
Clinical Study
May 23, 2024
|
Clinical Study
May 23, 2024
|
Announcement
May 23, 2024
|
Financing Agreement
May 23, 2024
|
Product Service News
May 23, 2024
|
Announcement
May 23, 2024
|
Clinical Study
May 23, 2024
|
Product Service News
May 23, 2024
|
Product Service News
May 23, 2024
|
Product Service News
May 23, 2024
|
|
|
|
Related News
|
Business Update
|
Business Update
|
|
Stocks
|
Announcement
|
Product Service News
|
Business Update
|
|
|
|
Business News
|
 Clinical Study
The pharmaceutical industry is abuzz with the exciting news of Corbus Pharmaceuticals Holdings, Inc. releasing updated Phase 1 clinical data for their revolutionary drug, SYS-6002 (CRB-701). This groundbreaking advance in cancer treatment is set to be presented at the prestigious 2024 American Society of Clinical On...
|
|
Clinical Study
Innovative Therapeutic Approaches Show Promising Results in Oncology, Genetic Deafness, and Retinal Diseases The landscape of therapeutic interventions is witnessing groundbreaking advancements in the treatment of challenging diseases. Recent presentations at prominent medical conferences have highlighted important...
|
 Clinical Study
: Zentalis Pharmaceuticals has announced promising initial findings from its Phase 1 clinical trial exploring the efficacy and safety of azenosertib in combination with gemcitabine for the treatment of relapsed or refractory osteosarcoma. These results are set to be presented at the 2024 American Society of Clinical...
|
|
Clinical Study
In recent news, Cogent Biosciences, Inc. has shared positive updated lead-in data from their ongoing Phase 3 PEAK trial. The trial assesses the efficacy of bezuclastinib, a selective and potent KIT mutant inhibitor, in combination with sunitinib for the treatment of Gastrointestinal Stromal Tumors (GIST). These find...
|
 Clinical Study
CSIMarket.com - May 23, 2024HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a biopharmaceutical company focused on developing immunotherapeutics based on its innovative arenavirus platform, recently released updated positive results from its Phase 1/2 clinical trial of HB-200. The trial investigated the potential of ...
|
Our Most Popular Articles
|
 Announcement
In a recent development, Varonis Systems Inc, a leading data security firm, has announced the integration of prompt monitoring within its highly regarded Microsoft 365 Copilot security offering. This advanced AI-driven monitoring solution is set to reinforce protection against malicious copilot activity, ensuring en...
|
 Business Update
Elastic (NYSE: ESTC), the leading Search AI company based in San Francisco, has made significant strides in enhancing its Elasticsearch platform s capabilities with new updates and recognitions. The latest announcements solidify Elastic s commitment to creating cutting-edge solutions for AI-driven search application...
|
 Management Changes
DALLAS, Jan. 12, 2024 - Dorchester Minerals, L.P. (NASDAQ-DMLP), a prominent player in the Energy sector, has announced the appointment of Ms. Lesley Carver as the newly appointed manager of the board of managers of Dorchester Minerals Management GP LLC, effective January 10, 2024. The notification was rec...
|
More News
|
 Announcement
Breakthrough Results for EVX-01: Promising New Data from Phase 2 Study to be Presented at ASCO 2024 COPENHAGEN, Denmark, May 23, 2024 Evaxion Biotech A/S (NASDAQ: EVAX), a pioneering company in the development of AI-Immunology powered vaccines, is set to present promising new data from its ongoing Phase 2 study ...
|
 Clinical Study
In recent years, the field of immuno-oncology has witnessed groundbreaking advancements that offer new hope for cancer patients. Mural Oncology, a leading clinical-stage immuno-oncology company, has been at the forefront of this innovation. Two significant developments came to light recently: the presentation of cli...
|
|
Clinical Study
Kymera Therapeutics, a leading biotechnology company, is set to make significant scientific contributions at various upcoming medical conferences, presenting new clinical data from their ongoing Phase 1 trials of MDM2 Degrader KT-253 and STAT3 Degrader KT-333. The company s recent announcement regarding scientific p...
|
 Clinical Study
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual MeetingLifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical StudyAuthor NameDateThe world of cancer treatmen...
|
 Clinical Study
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., April 08, 2024 Merus N.V. (Nasdaq: MRUS), a clinical-stage company known for its innovative approach in the development of multispecific antibodies (Biclonics® and Triclonics®), is making substantial strides in the oncology field with the announcement of several pi...
|
|
Clinical Study
Candel Therapeutics, a clinical stage biopharmaceutical company, has recently made significant advancements in the development of multimodal biological immunotherapies to combat cancer. The company s innovative approach aims to address the limitations of current treatment options and improve outcomes for patients wi...
|
 Clinical Study
Werewolf Therapeutics, a leader in innovative biotherapeutic developments, is poised to present the latest clinical trial data of its groundbreaking candidate WTX-124 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The updated results from their ongoing Phase 1/1b clinical trial will highlig...
|
 Clinical Study
The emerging field of precision medicine holds tremendous promise for revolutionizing cancer treatment. In this article, we delve into the latest groundbreaking developments presented by IN8bio at the highly anticipated 2024 ASCO Annual Meeting. The pharmaceutical company shares its eagerly awaited Phase 1 study dat...
|
 Announcement
HUB Security Delays Annual Report Filing: Implications for the Cybersecurity Firm In an important announcement for investors and stakeholders, HUB Cyber Security Ltd. (Nasdaq: HUBC), a leading developer in the realm of confidential computing cybersecurity solutions and advanced data services, revealed it requires ad...
|
 Financing Agreement
Munich-based Lilium N.V. (NASDAQ: LILM), a leading developer of all-electric vertical take-off and landing (eVTOL) jets and a trailblazer in Regional Air Mobility (RAM), unveiled its plans to launch a comprehensive underwritten public offering for its Class A ordinary shares, together with warrants to purc...
|
 Product Service News
CooperCompanies 2023 Environmental, Social, and Governance Report Highlights Efforts that Benefit People and the PlanetSAN RAMON, Calif., May 23, 2024 - CooperCompanies (Nasdaq: COO), a global leader in medical devices, today unveiled its highly anticipated 2023 Environmental, Social, and Governance (ESG) Report. Th...
|
 Announcement
Quanex Building Products Prepares for Second Quarter 2024 Earnings ReportQuanex Building Products Corporation (NYSE: NX), a well-known manufacturer of engineered materials and components for the building products market, has announced plans to release its second quarter 2024 financial results. The announcement is s...
|
 Clinical Study
Epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures, affects millions of individuals worldwide. Despite numerous available treatments, a significant percentage of patients continue to suffer from uncontrolled seizures, highlighting the dire need for new therapeutic avenues. Supernus Pharmaceuticals, Inc., a company renowned for its innovative approach to neurological and psychiatric diseases, has recently announced promising interim data from its ongoing open-label Phase 2a study of SPN-817, their novel, highly selective acetylcholinesterase (AChE) inhibitor. Unveiling SPN-817: A Novel Approach in Epilepsy TreatmentSPN-817 represents a significant advancement in epilepsy treatment due to its innovative mechanism of action. Unlike traditional anti-epileptic drugs (AEDs), which typically target ion channels or neurotransmitter receptors, SPN-817 operates through the selective inhibition of acetylcholinesterase. This action leads to increased levels of acetylcholine in the central nervous system, impacting neuronal excitability and synaptic plasticity, which could potentially modulate seizure activity.
|
 Product Service News
LPL Financial Reports Robust Monthly Activity for April 2024 SAN DIEGO, May 23, 2024 LPL Financial LLC (LPL Financial), a wholly owned subsidiary of LPL Financial Holdings Inc. (Nasdaq: LPLA), today unveiled its monthly activity report for April 2024, showcasing significant advancements and robust performance in...
|
 Product Service News
The tide of outdoor participation is rising, and Winnebago Industries is riding the wave to illuminate the burgeoning health benefits of outdoor activities. The Eden Prairie-based manufacturer of outdoor recreation products has released its fourth annual Winnebago Industries Spotlight Survey, showcasing a significan...
|
 Product Service News
Verita CSG Introduces Series of Innovative Insurance Solutions May 23, 2024 CSIMarket.com Verita CSG, Inc. (Verita), a managing general underwriting (MGU) company known for its forward-thinking insurance solutions, announced several groundbreaking products this quarter aimed at enhancing insurance coverage acro...
|
|
|
|
|
